Bone Pain and Muscle Weakness in Cancer Patients

Daniel P. Milgrom, Neha L. Lad, Leonidas Koniaris, Teresa Zimmers

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Purpose of Review: In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. Recent Findings: There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. Summary: CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.

Original languageEnglish (US)
Pages (from-to)76-87
Number of pages12
JournalCurrent Osteoporosis Reports
Volume15
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Bone Neoplasms
Muscle Weakness
Muscle Neoplasms
Bone and Bones
Pain
Neoplasms
Therapeutics
Androgen Receptors
Nerve Fibers
Morbidity
Research

Keywords

  • Bone metastasis
  • Cachexia
  • Cancer-induced bone pain
  • Muscle weakness

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Bone Pain and Muscle Weakness in Cancer Patients. / Milgrom, Daniel P.; Lad, Neha L.; Koniaris, Leonidas; Zimmers, Teresa.

In: Current Osteoporosis Reports, Vol. 15, No. 2, 01.04.2017, p. 76-87.

Research output: Contribution to journalReview article

Milgrom, Daniel P. ; Lad, Neha L. ; Koniaris, Leonidas ; Zimmers, Teresa. / Bone Pain and Muscle Weakness in Cancer Patients. In: Current Osteoporosis Reports. 2017 ; Vol. 15, No. 2. pp. 76-87.
@article{7b10bc259bf64d6ab383f1f0d55a4d27,
title = "Bone Pain and Muscle Weakness in Cancer Patients",
abstract = "Purpose of Review: In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. Recent Findings: There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. Summary: CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.",
keywords = "Bone metastasis, Cachexia, Cancer-induced bone pain, Muscle weakness",
author = "Milgrom, {Daniel P.} and Lad, {Neha L.} and Leonidas Koniaris and Teresa Zimmers",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s11914-017-0354-3",
language = "English (US)",
volume = "15",
pages = "76--87",
journal = "Current Osteoporosis Reports",
issn = "1544-1873",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Bone Pain and Muscle Weakness in Cancer Patients

AU - Milgrom, Daniel P.

AU - Lad, Neha L.

AU - Koniaris, Leonidas

AU - Zimmers, Teresa

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose of Review: In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. Recent Findings: There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. Summary: CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.

AB - Purpose of Review: In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. Recent Findings: There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. Summary: CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.

KW - Bone metastasis

KW - Cachexia

KW - Cancer-induced bone pain

KW - Muscle weakness

UR - http://www.scopus.com/inward/record.url?scp=85019124329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019124329&partnerID=8YFLogxK

U2 - 10.1007/s11914-017-0354-3

DO - 10.1007/s11914-017-0354-3

M3 - Review article

VL - 15

SP - 76

EP - 87

JO - Current Osteoporosis Reports

JF - Current Osteoporosis Reports

SN - 1544-1873

IS - 2

ER -